PharmaVentures Monthly Podcast Series
The Future of Diagnostics and the Impact on Deals
Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals.
The Involvement of Law and Tax in Deal Making
Listen as Colin McCall, Partner – Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process.
Commercial Due Diligence and the Deal Making Process
Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.
Financial and Technical Aspects Driving Today’s Life Sciences Deal Making
Listen as Andrew Guise gives key insight into the deal making landscape – asset value, accessing the market, positioning and the actual deal process in the current economic climate – from the unique position standing astride both the financial world and the technical world translating science into value.
Current Challenges for CROs and CDMOs in Drug Development and Supply
Listen as Frank Dollard, Steve Garland and Jansen Jacob discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice.
4 Common Mistakes in Partnering
Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.
The Importance of Pricing and Market Access in Licensing, Partnering and Early-Stage Development
Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.
Medical Device and In Vitro Diagnostic Regulations are changing. How will you be affected?
Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK. A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.
The Korean Partnering Opportunity for Western Biopharmaceutical Companies
Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine.
The Role of CDMOs in a Fast Evolving Manufacturing Landscape
Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine.
Robust Valuations of Life Science Companies, Assets and Licensing Deals
Listen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience is combined with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals
Review of 2022: M&A, Licensing and Fundraising
Listen as Fintan Walton, PharmaVentures’ CEO and Founder, reflects on this year’s deal trends in M&A, Licensing and Fundraising, considers the significant macroeconomic events, and offers insight into what impact they may have on the global pharma and biotech industry in 2023.